<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>Untitled Document</title><style>body {	margin:0;}</style></head><body>    <table width="550px" cellpadding="0" cellspacing="0">
        <tr>
            <td>
                <img src="images/spacer.gif" height="20px" width="25px" />
            </td>
            <td height="15px">
                <font size="1" color="#000000" face="arial, sans-serif">Is this e-mail not displaying correctly? <a href="#" style="color:#0067b1">View this e-mail in your browser</a>.</font>
            </td>
        </tr>
    </table>    <table width="550px" cellpadding="0" cellspacing="0">
        <!--BEGIN HEADER-->
        <tr>
            <td>
                <img src="images/header_top.jpg" />
            </td>
        </tr>
        <tr>
            <td>
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td height="113px" width="90px">
                            <img src="images/header1.jpg" />
                        </td>
                        <td valign="center" width="320px">
                            <font size="4" color="#00aa86" face="arial, sans-serif"><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;ONLY ZYLET<sup style="font-size: 10px; line-height: 0; vertical-align: 6px">&reg;</sup> COMBINES THE<br />&nbsp;&nbsp;&nbsp;ANTI-INFLAMMATORY EFFICACY<br />&nbsp;&nbsp;OF LOTEPREDNOL ETABONATE<br />&nbsp;WITH THE ANTIBIOTIC ACTIVITY<br />OF TOBRAMYCIN</em></strong></font>
                        </td>
                        <td>
                            <img src="images/logo_zylet_header.jpg" alt="Zylet Logo" />
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr>
            <td>
                <img src="images/header_bottom.jpg" />
            </td>
        </tr><!--END HEADER-->

        <tr>
            <td align="center" height="25px" valign="center">
                <font face="arial, sans-serif" size="2" color="#000000"><strong><em>Visit <a href="http://www.BauschSampleVault.com" style="color:#000000">www.BauschSampleVault.com</a> to order FREE ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 4px">&reg;</sup> samples<br />for your patients.</em></strong></font>
            </td>
        </tr>

        <!--BEGIN MAIN IMAGE/GRAPHIC-->
        <tr>
            <td>
                <table cellpadding="2" cellspacing="0">
                    <tr>
                        <td>
                            <img src="images/spacer.gif" height-"10px"=height-"10px" width="15px" />
                        </td>
                        <td align="center" bgcolor="#f2f6d5" height="160px" valign="center" width="510px" style="border:1px solid #00aa86">
                            <table cellpadding="0" cellspacing="0" width="500px">
                                <tr>
                                    <td valign="top">
                                        <img src="images/main_image.jpg" alt="Eye Image" />
                                    </td>
                                    <td width="330px" valign="top">
                                        <table cellpadding="0" cellspacing="0">
                                            <tr>
                                                <td align="center" bgcolor="#cbdb2a" height="38" valign="center">
                                                    <font face="arial, sans-serif" size="2" color="#0067b1"><strong>Treat the signs of blepharitis with ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 4px">&reg;</sup></strong></font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td align="left" bgcolor="#e3ea9a" height="24px" valign="center">
                                                    <font face="arial, sans-serif" size="2" color="#000000">&nbsp;&nbsp;ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 4px">&reg;</sup> effectively reduced these signs of<br />&nbsp;&nbsp;blepharitis by approximately 70%<sup style="font-size: 8px; line-height: 0; vertical-align: 4px">1</sup>:</font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td align="left" bgcolor="#cbdb2a" height="24px" valign="center" width="330px">
                                                    <font face="arial, sans-serif" size="2" color="#000000">
                                                        &nbsp;&nbsp;<font color="#0067b1">•</font> Hyperemia
                                                        <br />&nbsp;&nbsp;<font color="#0067b1">•</font> Scaling or crusting
                                                        <br />&nbsp;&nbsp;<font color="#0067b1">•</font> Margin hypertrophy
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        <strong>&nbsp;&nbsp;Study design:</strong> A parallel-group, double-masked, randomized,<br />
                                                        &nbsp;&nbsp;prospective study involving 17 independent centers with 276 healthy<br />
                                                        &nbsp;&nbsp;adult volunteers who were randomized to ZYLET<sup style="font-size: 7px; line-height: 0; vertical-align: 2px">&reg;</sup> (n=138) or<br />
                                                        &nbsp;&nbsp;TobraDex (n=138) administered 4 times daily for 14 days.<sup style="font-size: 6px; line-height: 0; vertical-align: 2px">1</sup>
                                                    </font>
                                                </td>
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                        </td>
                        <td></td>
                    </tr>
                </table>
            </td>
        </tr><!--END MAIN IMAGE/GRAPHIC-->
        <!--BEGIN ISI-->
        <tr>
            <td>
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td width="25px">
                            <img src="images/spacer.gif" width="25px" />
                        </td>
                        <td>
                            <table cellpadding="1" cellspacing="1">
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#00aa86"><strong>Indications and Usage</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <table cellpadding="0" cellspacing="0">
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 2px">&reg;</sup> (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) is a topical anti-infective and steroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
                                                    </font>
                                                </td>
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                            <table cellpadding="1" cellspacing="1">
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#00aa86"><strong>Important Risk Information</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <table cellpadding="0" cellspacing="0">
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 2px">&reg;</sup>
                                                        is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial
                                                        herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella,
                                                        and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steriods should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        Use of corticosteroids may result in posterior subcapsular cataract formation.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        The use of steriods after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as a slit lamp biomicroscopy and, where appropriate, fluorescein staining.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        Employment of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex).
                                                    </font>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10px" valign="top">
                                                    •
                                                </td>
                                                <td>
                                                    <font face="arial, sans-serif" size="1" color="#000000">
                                                        Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
                                                    </font>
                                                </td>
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                            <table cellpadding="1" cellspacing="1">
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#00aa86"><strong>Adverse Reactions</strong></font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#000000">
                                            Most common adverse reactions reported in patients were injection and superficial punctate keratitis, increased intraocular pressure, burning and stinging upon instillation.
                                        </font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#000000">
                                            <strong>Please see complete information about ZYLET<sup style="font-size: 8px; line-height: 0; vertical-align: 2px">&reg;</sup> in the full prescribing information provided <a href="http://www.bausch.com/en/ECP/Our-Products/Rx-Pharmaceuticals/Rx-Pharmaceuticals-ECP/~/media/Files/Package-Inserts/Pharma/Zylet-package-insert.ashx" style="color:#0067b1;">here</a>.</strong>
                                        </font>
                                    </td>
                                </tr>
                                <tr>
                                    <td>
                                        <font face="arial, sans-serif" size="1" color="#000000"><strong>Reference:</strong> 1. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. <em>Curr Med Res Opin</em>. 2008;24(1):287-296.</font><br />&nbsp;
                                    </td>
                                </tr>
                            </table>
                            <!-- END ISI -->

                            <!--BEGIN FOOTER-->
                            <table cellpadding="1" cellspacing="1">
                                <tr>
                                    <td valign="top" width="351px">
                                        <img src="images/logo_bausch_lomb.jpg" alt="Bausch &amp; Lomb Logo" /><br />
                                        <font face="arial, sans-serif" size="1" color="#000000">
                                            ZYLET is a registered trademark of Bausch & Lomb Incorporated.<br />
                                            ©2014 Bausch & Lomb Incorporated. US/ZYL/14/0004B 1/14<br />
                                            If you no longer wish to receive e-mails from Bausch + Lomb<br />
                                            about ZYLET<sup style="font-size: 7px; line-height: 0; vertical-align: 3px">&reg;</sup>, <a href="http://www.bausch.com/en/ECP/EmailOptOut" style="color:#0067b1;">unsubscribe here</a>.
                                        </font>
                                    </td>
                                    <td valign="top">
                                        <img src="images/logo_zylet_footer.jpg" alt="Zylet Logo" />
                                    </td>
                                </tr>
                            </table><!--END FOOTER-->

                        </td>
                    </tr>
                </table>
            </td>
        </tr>

    </table></body></html>